While rashes are not listed as primary adverse effects in major clinical trials, localized injection site irritation and rare dermatological events do occur in some individuals
Most adverse events reported in long-term trials are gastrointestinalnausea, vomiting, and constipationwhich typically decrease after 812 weeks as the body adapts
Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A
The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital
In this section, we discuss the range of effects and uses of this powerful GIP/GLP-1 co-agonist
Understanding why your current treatment may not be working is the first step toward finding a solution that aligns with your body's unique physiology
